A monoclonal antibody‐based immunoassay for measuring the potency of 2009 pandemic influenza <scp>H</scp>1<scp>N</scp>1 vaccines

Abstract

This study demonstrates the general feasibility of the mAb approach and strongly suggests that such ELISAs have potential for continued development as an alternative method to assay the potency of inactivated influenza vaccines.